Cargando…

Combination of immune check inhibitor and immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis: A case report

The present study selected two patients with lung cancer and epidermal growth factor receptor (EGFR) mutations who were treated with a programmed cell death protein 1 (PD-1) antibody and an immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis. In the first case, a 67-year-old fem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kobayashi, Kunihiko, Kaira, Kyoichi, Iemura, Hidetoshi, Shinomiya, Shun, Hashimoto, Kosuke, Miura, Yu, Shiono, Ayako, Nishihara, Fuyumi, Kagamu, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461616/ https://www.ncbi.nlm.nih.gov/pubmed/34631053 http://dx.doi.org/10.3892/mco.2021.2390

Ejemplares similares

Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non‐small cell lung cancer harboring EGFR mutation
por: Yamaguchi, Ou, et al.
Publicado: (2020)

Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer
por: Uchida, Takahiro, et al.
Publicado: (2019)

Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients
por: Shiono, Ayako, et al.
Publicado: (2019)

Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events
por: Miura, Yu, et al.
Publicado: (2020)

Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non‐small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2022)

Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
por: Yamaguchi, Ou, et al.
Publicado: (2019)

Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab
por: Yamaguchi, Ou, et al.
Publicado: (2020)

Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers
por: Mouri, Atsuto, et al.
Publicado: (2021)

Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs
por: Mouri, Atsuto, et al.
Publicado: (2021)

Clinical impact of post‐progression survival on overall survival in patients receiving nivolumab monotherapy as a second‐line treatment for advanced non‐small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2021)

Single-Cell Analysis Reveals a CD4(+) T-cell Cluster That Correlates with PD-1 Blockade Efficacy
por: Kagamu, Hiroshi, et al.
Publicado: (2022)

Establishing a whole blood CD4(+) T cell immunity measurement to predict response to anti-PD-1
por: Yamaguchi, Ou, et al.
Publicado: (2022)

Metachronous lesions in the orbit, retroperitoneum, and pleura of mucosa‐associated lymphoid tissue lymphoma: A case report
por: Shiono, Ayako, et al.
Publicado: (2022)

Tumor metabolic volume by (18)F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%
por: Yamaguchi, Ou, et al.
Publicado: (2020)

Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer
por: Hashimoto, Kosuke, et al.
Publicado: (2020)

Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR ‐major mutant NSCLC receiving osimertinib
por: Kaira, Kyoichi, et al.
Publicado: (2023)

Spontaneous aspiration of a long tree twig as foreign body
por: Hashimoto, Kosuke, et al.
Publicado: (2019)

Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer
por: Mouri, Atsuto, et al.
Publicado: (2019)

Primary thymic adenocarcinoma with an aggressive clinical course: An autopsy case showing signet ring cell‐like features
por: Shiono, Ayako, et al.
Publicado: (2020)

Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer
por: Kaira, Kyoichi, et al.
Publicado: (2023)

Potential of VEGFR2 expression as a predictive marker of PD-1 blockade in patients with advanced NSCLC
por: Kaira, Kyoichi, et al.
Publicado: (2022)

Automated glycan assembly of arabinomannan oligosaccharides from Mycobacterium tuberculosis
por: Pardo-Vargas, Alonso, et al.
Publicado: (2019)

Osimertinib induced cardiomyopathy: A case report
por: Shinomiya, Shun, et al.
Publicado: (2020)

Features and protective efficacy of human mAbs targeting Mycobacterium tuberculosis arabinomannan
por: Liu, Yanyan, et al.
Publicado: (2023)

Enhanced control of Mycobacterium tuberculosis extrapulmonary dissemination in mice by an arabinomannan-protein conjugate vaccine
por: Prados-Rosales, Rafael, et al.
Publicado: (2017)

Prospective assessment using (18)F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancer
por: Yamaguchi, Ou, et al.
Publicado: (2022)

Effects of infection and disease with Mycobacterium tuberculosis on serum antibody to glucan and arabinomannan: two surface polysaccharides of this pathogen
por: Keitel, Wendy A, et al.
Publicado: (2013)

Expedient synthesis of the heneicosasaccharyl mannose capped arabinomannan of the Mycobacterium tuberculosis cellular envelope by glycosyl carbonate donors
por: Islam, Maidul, et al.
Publicado: (2017)

Monoclonal antibodies from humans with Mycobacterium tuberculosis exposure or latent infection recognize distinct arabinomannan epitopes
por: Ishida, Elise, et al.
Publicado: (2021)

A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress)
por: Kaira, Kyoichi, et al.
Publicado: (2020)

Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer
por: Kaira, Kyoichi, et al.
Publicado: (2023)

A Th1-like CD4(+) T-cell Cluster That Predicts Disease-free Survival in Early-stage Lung Cancer
por: Yanagihara, Akitoshi, et al.
Publicado: (2023)

Value of (18)F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Advanced Research on Immune Checkpoint Inhibitor Therapy
por: Imai, Hisao, et al.
Publicado: (2022)

Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer
por: Tsuda, Takeshi, et al.
Publicado: (2023)

Association of Human Antibodies to Arabinomannan With Enhanced Mycobacterial Opsonophagocytosis and Intracellular Growth Reduction
por: Chen, Tingting, et al.
Publicado: (2016)

Tumor immunity is related to (18)F‐FDG uptake in thymic epithelial tumor
por: Imai, Hisao, et al.
Publicado: (2021)

Mycobacterium gordonae-induced humidifier lung
por: Utsugi, Harue, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2i3ion7kesmsd1ven3vtdgame7